Halozyme Therapeutics Inc (HALO) - Net Assets
Based on the latest financial reports, Halozyme Therapeutics Inc (HALO) has net assets worth $503.92 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.22 Billion) and total liabilities ($1.72 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Halozyme Therapeutics Inc (HALO) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $503.92 Million |
| % of Total Assets | 22.69% |
| Annual Growth Rate | 52.3% |
| 5-Year Change | 140.87% |
| 10-Year Change | 746.12% |
| Growth Volatility | 31339.66 |
Halozyme Therapeutics Inc - Net Assets Trend (2001–2024)
This chart illustrates how Halozyme Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore HALO total assets for the complete picture of this company's asset base.
Annual Net Assets for Halozyme Therapeutics Inc (2001–2024)
The table below shows the annual net assets of Halozyme Therapeutics Inc from 2001 to 2024. For live valuation and market cap data, see market cap of Halozyme Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $363.82 Million | +334.11% |
| 2023-12-31 | $83.81 Million | -50.64% |
| 2022-12-31 | $169.80 Million | -13.79% |
| 2021-12-31 | $196.95 Million | +30.39% |
| 2020-12-31 | $151.05 Million | +64.60% |
| 2019-12-31 | $91.77 Million | -63.13% |
| 2018-12-31 | $248.89 Million | +19.45% |
| 2017-12-31 | $208.37 Million | +741.50% |
| 2016-12-31 | $-32.48 Million | -175.54% |
| 2015-12-31 | $43.00 Million | +3.98% |
| 2014-12-31 | $41.35 Million | +306.86% |
| 2013-12-31 | $-19.99 Million | -140.92% |
| 2012-12-31 | $48.85 Million | +348.19% |
| 2011-12-31 | $10.90 Million | -46.44% |
| 2010-12-31 | $20.35 Million | +194.80% |
| 2009-12-31 | $6.90 Million | -55.11% |
| 2008-12-31 | $15.38 Million | -73.38% |
| 2007-12-31 | $57.77 Million | +150.28% |
| 2006-12-31 | $23.08 Million | +26.77% |
| 2005-12-31 | $18.21 Million | +22.82% |
| 2004-12-31 | $14.82 Million | +147199.86% |
| 2003-12-31 | $10.06K | -88.41% |
| 2002-12-31 | $86.81K | +280.13% |
| 2001-12-31 | $22.84K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Halozyme Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 35990865200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $359.87 Million | 98.91% |
| Common Stock | $123.00K | 0.03% |
| Other Comprehensive Income | $3.83 Million | 1.05% |
| Total Equity | $363.82 Million | 100.00% |
Halozyme Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Halozyme Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
INPOST S.A UNSP.ADR/1/2
F:6690
|
$7.52 Billion |
|
Dpm Metals Inc.
AU:DPM
|
$7.52 Billion |
|
Zhongfu Shenying Carbon Fiber Co. Ltd. A
SHG:688295
|
$7.53 Billion |
|
Raia Drogasil S.A
SA:RADL3
|
$7.53 Billion |
|
NISSAN MOTOR SP. ADR/2
F:NISE
|
$7.52 Billion |
|
SHIZUOKA FIN. GROUP INC.
F:P2U
|
$7.51 Billion |
|
Anhui Yingliu
SHG:603308
|
$7.51 Billion |
|
Element Solutions Inc
NYSE:ESI
|
$7.48 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Halozyme Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 83,808,000 to 363,821,000, a change of 280,013,000 (334.1%).
- Net income of 444,091,000 contributed positively to equity growth.
- Share repurchases of 250,000,000 reduced equity.
- Other comprehensive income increased equity by 13,107,000.
- Other factors increased equity by 72,815,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $444.09 Million | +122.06% |
| Share Repurchases | $250.00 Million | -68.72% |
| Other Comprehensive Income | $13.11 Million | +3.6% |
| Other Changes | $72.81 Million | +20.01% |
| Total Change | $- | 334.11% |
Book Value vs Market Value Analysis
This analysis compares Halozyme Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 22.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3359.17x to 22.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $0.02 | $63.96 | x |
| 2002-12-31 | $0.02 | $63.96 | x |
| 2003-12-31 | $0.00 | $63.96 | x |
| 2004-12-31 | $0.42 | $63.96 | x |
| 2005-12-31 | $0.36 | $63.96 | x |
| 2006-12-31 | $0.37 | $63.96 | x |
| 2007-12-31 | $0.78 | $63.96 | x |
| 2008-12-31 | $0.19 | $63.96 | x |
| 2009-12-31 | $0.08 | $63.96 | x |
| 2010-12-31 | $0.22 | $63.96 | x |
| 2011-12-31 | $0.11 | $63.96 | x |
| 2012-12-31 | $0.44 | $63.96 | x |
| 2013-12-31 | $-0.18 | $63.96 | x |
| 2014-12-31 | $0.34 | $63.96 | x |
| 2015-12-31 | $0.34 | $63.96 | x |
| 2016-12-31 | $-0.25 | $63.96 | x |
| 2017-12-31 | $1.50 | $63.96 | x |
| 2018-12-31 | $1.73 | $63.96 | x |
| 2019-12-31 | $0.64 | $63.96 | x |
| 2020-12-31 | $1.07 | $63.96 | x |
| 2021-12-31 | $1.34 | $63.96 | x |
| 2022-12-31 | $1.21 | $63.96 | x |
| 2023-12-31 | $0.62 | $63.96 | x |
| 2024-12-31 | $2.81 | $63.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Halozyme Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 122.06%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 43.74%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 5.67x
- Recent ROE (122.06%) is above the historical average (-101.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -173.62% | -160.63% | 0.94x | 1.14x | $-41.94K |
| 2002 | -75.17% | -74.36% | 0.90x | 1.12x | $-73.94K |
| 2003 | -785.88% | -307.69% | 0.54x | 4.72x | $-80.10K |
| 2004 | -61.33% | 0.00% | 0.00x | 1.11x | $-10.57 Million |
| 2005 | -72.91% | -10435.88% | 0.01x | 1.13x | $-15.10 Million |
| 2006 | -63.91% | -1502.63% | 0.02x | 2.00x | $-17.06 Million |
| 2007 | -41.37% | -628.93% | 0.04x | 1.79x | $-29.67 Million |
| 2008 | -316.35% | -555.15% | 0.11x | 4.98x | $-50.19 Million |
| 2009 | -845.39% | -426.88% | 0.18x | 11.18x | $-59.05 Million |
| 2010 | -261.61% | -390.79% | 0.15x | 4.49x | $-55.28 Million |
| 2011 | -181.37% | -35.25% | 0.85x | 6.03x | $-20.86 Million |
| 2012 | -109.62% | -126.53% | 0.31x | 2.76x | $-58.44 Million |
| 2013 | 0.00% | -152.33% | 0.54x | 0.00x | $-81.48 Million |
| 2014 | -165.35% | -90.76% | 0.45x | 4.01x | $-72.51 Million |
| 2015 | -74.96% | -23.86% | 0.74x | 4.23x | $-36.53 Million |
| 2016 | 0.00% | -70.23% | 0.56x | 0.00x | $-99.77 Million |
| 2017 | 30.22% | 19.89% | 0.61x | 2.50x | $42.13 Million |
| 2018 | -32.28% | -52.90% | 0.34x | 1.77x | $-105.22 Million |
| 2019 | -78.72% | -36.86% | 0.35x | 6.17x | $-81.42 Million |
| 2020 | 85.46% | 48.24% | 0.46x | 3.84x | $113.98 Million |
| 2021 | 204.47% | 90.84% | 0.40x | 5.61x | $383.01 Million |
| 2022 | 119.04% | 30.62% | 0.36x | 10.85x | $185.15 Million |
| 2023 | 336.00% | 33.96% | 0.48x | 20.68x | $273.21 Million |
| 2024 | 122.06% | 43.74% | 0.49x | 5.67x | $407.71 Million |
Industry Comparison
This section compares Halozyme Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Halozyme Therapeutics Inc (HALO) | $503.92 Million | -173.62% | 3.41x | $7.52 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more